Corona Remedies Q1 FY27: Results date, call, guidance

What investors are tracking ahead of Q1 FY27

Corona Remedies Limited is approaching the Q1 FY27 results window with a set of dated events that matter for shareholders and the sell-side. The company’s board of directors is scheduled to meet on July 31, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. After that, an earnings conference call is set for August 3, 2026, where management is expected to walk through the quarter and answer questions from analysts and investors.

The stock has been in focus because multiple market snapshots and preview notes cited different trading levels and valuation metrics around early July 2026. One preview referenced shares trading at Rs. 2,041 with a market capitalisation of Rs. 12,287 Cr and a price-to-earnings multiple of 66.4. Another “quick details” block cited a CMP of Rs. 2,113 and market cap of Rs. 12,923.13 Cr. These are point-in-time figures, and readers should treat them as date-specific references rather than a single consistent quote.

Board meeting on July 31 to approve unaudited results

According to the disclosed schedule, the board meeting on July 31, 2026 will consider and approve Corona Remedies’ unaudited financial results for Q1 FY27. This date anchors the market’s near-term timeline and is typically when companies also make other statutory disclosures, if any, linked to the quarterly announcement.

The quarter in question is Q1 FY 2026-2027. The same data pack also flags the immediately preceding quarter’s operational base points, including previous quarter revenue of Rs. 353.1 Cr, PAT of Rs. 45.3 Cr, and an EBITDA margin of 17.6%. While Q1 FY27 numbers were not provided in the text, these prior-quarter figures give investors a reference for recent profitability and margins.

Earnings call scheduled for August 3, 2026

Corona Remedies has announced an analyst and investor conference call on Monday, August 3, 2026 at 11:30 AM IST to discuss Q1 FY27 performance. The company indicated participants can join via universal dial-in numbers or international toll-free lines, and a “Diamond Pass Link” was referenced as the registration link.

The call is set to be led by the senior leadership team: Managing Director and CEO Mr. Nirav Mehta, Joint Managing Director Mr. Ankur Mehta, and CFO Mr. Bhavin Bhagat. The stated purpose is a detailed review of the company’s results for the first quarter ended June 30, 2026.

FY27 growth guidance highlighted by management

The text includes management guidance targets for FY27, including a 15% organic revenue growth target and a 20% PAT growth target for the full year. It also states an ambition to outperform the broader Indian Pharmaceutical Market (IPM), which the note says sustained double-digit growth of 10.3% to 12.1% in the first two months of the quarter.

Separately, the same set of notes also mentions that Corona Remedies Limited targets revenue growth of 15% organically and 25% from the acquired portfolio in FY27. The broader IPM growth expectation for FY27 is also cited as about 10% to 10.3%, with volume growth expected at 1.5% to 2% and the rest driven by price and new launches.

Dividend update from the July 9 AGM

Corona Remedies held its 22nd Annual General Meeting on July 09, 2026, conducted via video conferencing. Shareholders approved a final dividend of Rs. 10 per equity share for FY26. The text also states this represents a 100% payout on the face value of Rs. 10 each.

The AGM also saw the approval of the audited financial statements for the year ended March 31, 2026. Shareholders passed all resolutions, including the re-appointment of Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for five years and the appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors.

Q1 FY27 preview ranges and what they are based on

A preview note in the text frames Q1 FY27 estimates using a “trailing-growth framework” applied to the company’s Q1 FY26 base of Rs. 349 Cr revenue and Rs. 46 Cr net profit. Using this approach, it provides a Q1 FY27 estimate range of Rs. 392-451 Cr for revenue and Rs. 58-74 Cr for PAT, implying year-on-year growth of +21.0% for revenue and +43.7% for net profit.

The same preview block also lists a 12-month target range of Rs. 2,368-2,634 (Uniresearch estimate). It further notes the results are expected in a July-August 2026 window, consistent with the broader NSE and BSE results season for the quarter ending June 2026.

Reported recent profit figures and quarterly operating data

The text includes multiple profit figures and quarterly snapshots across periods. It states profit of Rs. 185 Cr for Mar 2026, Rs. 149 Cr for Mar 2025, and Rs. 90.5 Cr for Mar 2024. Separately, it also mentions “Corona Remedies March-Quarter Consol Net Profit 453.3 Million Rupees” (dated May 11, 2026) and “Corona Remedies Dec-Quarter Consol Net Profit 412.7 Million Rupees” (announcement date Feb 02, 2026). Converted to crores, 453.3 million rupees is about Rs. 45.33 Cr and 412.7 million rupees is about Rs. 41.27 Cr.

A standalone quarterly table in the text lists net sales/income and net profit for select quarters such as Jun 30, 2025 (Net Sales/Income Rs. 346.54 Cr; Net Profit Rs. 46.40 Cr), Sep 30, 2025 (Net Sales/Income Rs. 361.13 Cr; Net Profit Rs. 52.15 Cr), and Dec 31, 2025 (Net Sales/Income Rs. 342.42 Cr; Net Profit Rs. 41.25 Cr). These are historical reference points and not Q1 FY27 numbers.

What the company does and where it competes

Corona Remedies is described as an India-focused branded pharmaceutical formulation company. It is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas. This positioning links its performance to domestic prescription trends and the growth trajectory of the IPM.

The same context also notes that an earnings call transcript does not provide specific details about the current or expected order book or pending orders. For investors, that means quarterly commentary and segment performance details, if any, become more important in the scheduled call.

Key numbers at a glance

Q1 FY27 estimate ranges cited in the preview

Market impact: what is confirmed so far

The confirmed market-moving items in the text are schedule-driven rather than performance-driven because the Q1 FY27 results numbers themselves are not disclosed here. The July 31 board meeting sets expectations for when unaudited financials will be formally approved. The August 3 call creates a second event where management will discuss performance and provide colour on the quarter.

Guidance is another key input already in the market. The company’s targets of 15% organic revenue growth and 20% PAT growth for FY27, along with an additional reference to 25% growth from an acquired portfolio, provide a benchmark against which future disclosures can be measured. The IPM growth references of about 10% to 10.3% for FY27 and 10.3% to 12.1% in the first two months of the quarter frame the industry backdrop that investors often use for relative comparison.

Analysis: why these dates and targets matter

For a domestic branded formulations business, quarterly disclosures and management commentary are closely watched for demand signals, prescription traction, and profitability trends. In this case, the schedule is clear: results approval on July 31 and a management-led call on August 3. The dividend approval at the AGM on July 9 also matters for investors tracking shareholder returns, especially since the final dividend was approved with 100% of votes cast in favour, as stated.

The preview ranges cited for Q1 FY27 (revenue Rs. 392-451 Cr and PAT Rs. 58-74 Cr) show the market is already working with a wide outcomes band. Because the text provides multiple point-in-time valuation references (including P/E cited as 66.4 in one note and 54.5 in another), investors may focus on the company’s own disclosures and the consistency of commentary with its FY27 guidance.

Conclusion

Corona Remedies’ immediate catalysts are the July 31, 2026 board meeting to approve Q1 FY27 unaudited results and the August 3, 2026 earnings call at 11:30 AM IST led by the CEO, Joint MD and CFO. Separately, shareholders have already approved a final dividend of Rs. 10 per share for FY26 at the July 9 AGM. The next concrete update, based on the provided information, is the company’s Q1 FY27 results discussion on the scheduled conference call.